355116-05-1Relevant academic research and scientific papers
SUBSTITUTED PHENYLSULFAMOYL COMPOUNDS AS PPAR AGONISTS
-
Page/Page column 66, (2010/11/28)
The present invention is directed at substituted phenylsulfamoyl compounds of Formula (I), pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activa
Cis-imidazolines
-
Page/Page column 17, (2008/06/13)
There are presented compounds of the formula or pharmaceutically acceptable salts thereof, wherein Y1, Y2, X1, X2, X3 and R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity.
SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS
-
Page/Page column 137, (2010/02/14)
The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
